FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Safety and immunogenicity of BPV-1 L1 virus-like particles i...
Equine veterinary journal2011; 44(1); 107-111; doi: 10.1111/j.2042-3306.2011.00390.x

Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses.

Abstract: Infection with bovine papillomaviruses types 1 and 2 (BPV-1, BPV-2) can lead to the development of therapy-resistant skin tumours termed sarcoids and possibly other skin diseases in equids. Although sarcoids seriously compromise the welfare of affected animals and cause considerable economic losses, no prophylactic vaccine is available to prevent this common disease. In several animal species and man, immunisation with papillomavirus-like particles (VLP) has been shown to protect efficiently from papillomaviral infection. Objective: BPV-1 L1 VLPs may constitute a safe and highly immunogenic vaccine candidate for protection of horses against BPV-1/-2-induced disease. Methods: Three groups of 4 horses each received 50, 100 or 150 µg of BPV-1 L1 VLPs, respectively, on Days 0, 28 and 168. Three control horses received adjuvant only. Horses were monitored on a daily basis for one week after each immunisation and then in 2 week intervals. Sera were collected immediately before, 2 weeks after each vaccination and one and 2 years after the final boost and analysed by pseudovirion neutralisation assay. Results: None of the horses showed adverse reactions upon vaccination apart from mild and transient swelling in 2 individuals. Irrespective of the VLP dose, all VLP-immunised horses had developed a BPV-1-neutralising antibody titre of ≥ 1600 plaque forming units (pfu)/ml 2 weeks after the third vaccination. Eight of 10 trial horses still available for follow-up had neutralising antibody titres ≥ 1600 pfu/ml one year and ≥ 800 pfu/ml 2 years after the last immunisation. Conclusions: Intramuscular BPV-1 L1 VLP vaccination in horses is safe and results in a long-lasting antibody response against BPV-1. Neutralisation titres were induced at levels that correlate with protection in experimental animals and man. Conclusions: BPV-1 L1 VLPs constitute a promising vaccine candidate for prevention of BPV-1/-2-induced disease in equids.
© 2011 EVJ Ltd.
Get Full Text
Publication Date: 2011-09-06 PubMed ID: 21895749PubMed Central: PMC3939654DOI: 10.1111/j.2042-3306.2011.00390.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Controlled Clinical Trial
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research study aims to test the safety and efficacy of a vaccine candidate, made from bovine papillomavirus-like particles (BPV-1 L1 VLPs), in protecting horses against skin diseases caused by bovine papillomaviruses. The study, which employed a dose-escalation trial design and included daily monitoring and follow-ups, showed that the vaccine appears to be safe and capable of inducing a long-term protective immune response in horses.

Objective of the Study

  • The study seeks to examine BPV-1 L1 VLPs as potentially safe and highly effective vaccines meant for safeguarding horses against diseases induced by bovine papillomaviruses types 1 and 2 (BPV-1, BPV-2). These diseases are exemplified by skin tumours, known as sarcoids, which are difficult to treat and can cause significant economic losses.

Methodology

  • The study involved three groups of four horses each, receiving different doses (50, 100, or 150 µg) of BPV-1 L1 VLPs on days 0, 28, and 168. Another group of three horses formed the control group, only receiving adjuvants.
  • The horses were closely observed daily for a week after each administration and subsequently at intervals of two weeks.
  • The researchers collected serum samples both before and two weeks after each vaccination, and then again one and two years after the final dose. Those samples were analyzed using a pseudovirion neutralisation assay.

Results

  • Observers did not identify any adverse reactions to the vaccination, other than mild and short-lived swelling in two subjects.
  • All vaccinated horses developed a BPV-1 neutralizing antibody titre of at least 1600 plaque forming units (pfu)/ml two weeks after the third vaccination, regardless of the VLP dose administered.
  • At one-year and two-year follow-ups, eight of the ten horses still available maintained neutralising antibody titres of over 1600 pfu/ml and 800 pfu/ml, respectively.

Conclusions

  • The study concludes that intramuscular vaccination with BPV-1 L1 VLPs in horses is safe and induces a long-lasting antibody response against BPV-1. This was determined by the neutralisation titres generated, which were at levels that correlate with protection.
  • Given these promising results, BPV-1 L1 VLPs serves as a viable candidate for vaccination against BPV-1/-2-induced diseases in horses, making future prevention of these common and economically damaging diseases a distinct possibility.

Cite This Article

APA
Hainisch EK, Brandt S, Shafti-Keramat S, Van den Hoven R, Kirnbauer R. (2011). Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses. Equine Vet J, 44(1), 107-111. https://doi.org/10.1111/j.2042-3306.2011.00390.x

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 44
Issue: 1
Pages: 107-111

Researcher Affiliations

Hainisch, E K
  • Large Animal Surgery and Orthopaedics, Equine Clinic, University of Veterinary Medicine, Vienna, Austria.
Brandt, S
    Shafti-Keramat, S
      Van den Hoven, R
        Kirnbauer, R

          MeSH Terms

          • Animals
          • Antibodies, Neutralizing / blood
          • Antibodies, Viral / blood
          • Bovine papillomavirus 1 / immunology
          • Dose-Response Relationship, Immunologic
          • Horse Diseases / prevention & control
          • Horses
          • Viral Vaccines / adverse effects
          • Viral Vaccines / immunology

          Grant Funding

          • P 18990 / Austrian Science Fund FWF

          References

          This article includes 47 references
          1. Amtmann E, Müller H, Sauer G. Equine connective tissue tumours contain unintegrated bovine papilloma virus DNA. J. Virol. 1980;35:962–964.
            pmc: PMC288890pubmed: 6252350
          2. Ashrafi GH, Piuko K, Burden F, Yuan Z, Gault EA, Muller M, Trawford A, Reid SW, Nasir L, Campo MS. Vaccination of sarcoid-bearing donkeys with chimeric virus-like particles of bovine papillomavirus type 1. J. Gen. Virol. 2008;89:148–157.
            pubmed: 18089738
          3. Borzacchiello G, Roperto F. Bovine papillomaviruses, papillomas and cancer in cattle. Vet. Res. 2008;39:45.
            pubmed: 18479666doi: 10.1051/vetres:2008022google scholar: lookup
          4. Brandt S, Haralambus R, Shafti-Keramat S, Steinborn R, Stanek C, Kirnbauer R. A subset of equine sarcoids harbours BPV-1 DNA in a complex with L1 major capsid protein. Virology 2008;375:433–441.
            pubmed: 18395238
          5. Brandt S, Tober R, Corteggio A, Burger S, Sabitzer S, Walter I, Kainzbauer C, Steinborn R, Nasir L, Borzacchiello G. BPV-1 infection is not confined to the dermis but also involves the epidermis of equine sarcoids. Vet. Microbiol. 2011a;150:35–40.
            pubmed: 21242040doi: 10.1016/j.vetmic.2010.12.021google scholar: lookup
          6. Brandt S, Schoster A, Tober R, Kainzbauer C, Burgstaller JP, Haralambus R, Steinborn R, Hinterhofer C, Stanek C. Consistent detection of bovine papillomavirus in lesions, intact skin and peripheral blood mononuclear cells of horses affected by hoof canker. Equine vet. J. 2011b;43:202–209.
            pubmed: 21592216doi: 10.1111/j.2042-3306.2010.00147.xgoogle scholar: lookup
          7. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 1995;69:3959–3963.
            pmc: PMC189126pubmed: 7745754
          8. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 2004;78:751–757.
            pmc: PMC368835pubmed: 14694107
          9. Buck CB, Pastrana DV, Lowy DR, Schiller JT. [Last update 2008, 01.02.2009. Accessed 2009, 12/02];Production of papillomaviral vectors (pseudoviruses) 2008 http://home.ccr.cancer.gov/lco/pseudovirusproduction.htm
          10. Campo MS. Introduction. In: Campo MS, editor. Papillomavirus Research: From Natural History to Vaccines and Beyond. Caister Academic Press; Norfolk: 2006a. pp. 1–2.
          11. Campo MS. Bovine papillomavirus: Old system, new lessons? In: Campo MS, editor. Papillomavirus Research: From Natural History to Vaccines and beyond. Caister Academic Press; Norfolk: 2006b. pp. 373–387.
          12. Carr EA, Theon AP, Madewell BR, Griffey SM, Hitchcock ME. Bovine papillomavirus DNA in neoplastic and nonneoplastic tissues obtained from horses with and without sarcoids in the western United States. Am. J. vet. Res. 2001;62:741–744.
            pubmed: 11341396
          13. Chambers G, Ellsmore VA, O’Brien PM, Reid SW, Love S, Campo MS, Nasir L. Association of bovine papillomavirus with the equine sarcoid. J. Gen. Virol. 2003;84:1055–1062.
            pubmed: 12692268
          14. Fermaglich DH, Horohov DW. The effect of aging on immune responses. Vet. Clin. N. Am.: Equine Pract. 2002;18:621–630.
            pubmed: 12516937
          15. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 1993;67:315–322.
            pmc: PMC237365pubmed: 8380079
          16. Hainisch EK, Hartl B, Kainzbauer C, Tober R, Shafti-Keramat S, Kirnbauer R, Brandt S. Intact BPV-1 virion is required for experimental tumour induction in foals and causes viraemia. Proceedings of the 26th International Papillomavirus Conference; Montreal, Canada July 3-8 2010; 2010.
          17. Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen O, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch X, Dillner J, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Lu S, Vuocolo S, Hesley TM, Haupt RM, Barr E. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008;26:6844–6851.
            pubmed: 18930097
          18. Kirnbauer R. Papillomavirus-like particles for serology and vaccine development. Intervirology 1996;39:54–61.
            pubmed: 8957670
          19. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 1992;89:12180–12184.
            pmc: PMC50722pubmed: 1334560
          20. Kirnbauer R, Chandrachud LM, O’Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996;219:37–44.
            pubmed: 8623552
          21. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR, Schiller JT. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 1993;67:6929–6936.
            pmc: PMC238150pubmed: 8230414
          22. Lancaster WD. Apparent lack of integration of bovine papillomavirus DNA in virus induced equine and bovine tumour cells and virus transformed mouse cells. Virology 1981;108:251–255.
            pubmed: 6258289
          23. Lindblad EB. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 2004;82:497–505.
            pubmed: 15479435
          24. Marchetti B, Gault EA, Cortese MS, Yuan Z, Ellis SA, Nasir L, Campo MS. Bovine papillomavirus type 1 oncoprotein E5 inhibits equine MHC class I and interacts with equine MHC I heavy chain. J. Gen. Virol. 2009;90:2865–2870.
            pubmed: 19675187
          25. Mattil-Fritz S, Scharner D, Piuko K, Thones N, Gissmann L, Müller H, Müller M. Immunotherapy of equine sarcoid: Dose-escalation trial for the use of chimeric papillomavirus-like particles. J. Gen. Virol. 2008;89:138–147.
            pubmed: 18089737
          26. Nasir L, Campo MS. Bovine papillomaviruses: Their role in the aetiology of cutaneous tumours of bovids and equids. Vet. Dermatol. 2008;19:243–254.
            pubmed: 18927950
          27. O’Brien PM, Campo MS. Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res. 2002;88:103–117.
            pubmed: 12297330
          28. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931–4939.
            pubmed: 17499406
          29. Otten N, von Tscharner C, Lazary S, Antczak DF, Gerber H. DNA of bovine papillomavirus type 1 and 2 in equine sarcoids: PCR detection and direct sequencing. Arch. Virol. 1993;132:121–131.
            pubmed: 8394687
          30. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow S, Apter DL, Kitchener HC. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161–2170.
            pubmed: 17602732
          31. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, Fitzgerald PC, Kruger Kjaer S, Lowy DR, Schiller JT. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004;321:205–216.
            pubmed: 15051381
          32. Pastrana DV, Gambhira R, Buck CB, Pang Y-S, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RBS. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005;337:365–372.
            pubmed: 15885736
          33. Robl MG, Gordon DE, Lee KP, Olson C. Intracranial fibroblastic neoplasms in the hamster from bovine papilloma virus. Cancer Res. 1972;32:2221–2225.
            pubmed: 4343012
          34. Roden RBS, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J. Virol. 1996;70:3298–3301.
            pmc: PMC190197pubmed: 8627814
          35. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of virus-like particles. J. Virol. 1993;67:1936–1944.
            pmc: PMC240261pubmed: 8383219
          36. Schiller JT. [Last update 1997, 30.6.1997. Accessed 2009, 12/02];pSHELL. 1997 http://home.ccr.cancer.gov/lco/pSheLL.htm
          37. Schiller JT. [Last update 1998, 10.3.1998. Accessed 2009, 12/02];pYSEAP. 1998 http://home.ccr.cancer.gov/lco/pYSEAP.htm
          38. . Papillomavirus vaccines. 2007. pp. 337–369.
          39. Scott DW, Miller WH. Jr. Equine Dermatology. 2003. Sarcoid; pp. 719–731.
          40. Shafti-Keramat S, Schellenbacher C, Handisurya A, Christensen N, Reininger B, Brandt S, Kirnbauer R. Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes. Virology 2009;393:1–6.
            pmc: PMC3792341pubmed: 19729180
          41. Studer S, Gerber V, Straub R, Brehm W, Gaillard C, Luth A, Burger D. Prevalence of hereditary diseases in three-year-old Swiss Warmblood horses. Schweiz. Arch. Tierheilkd. 2007;149:161–171.
            pubmed: 17461391
          42. Sullins KE, Roberts SM, Lavach JD, Severin GA. Equine sarcoid. Equine Pract. 1986;8:21–27.
          43. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA 1995;92:11553–11557.
            pmc: PMC40440pubmed: 8524802
          44. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–278.
            pubmed: 15863374
          45. Voss JL. Transmission of equine sarcoid. Am. J. vet. Res. 1969;30:183–191.
            pubmed: 5392976
          46. Yuan Z, Philbey AW, Gault EA, Campo MS, Nasir L. Detection of bovine papillomavirus type 1 genomes and viral gene expression in equine inflammatory skin conditions. Virus Res. 2007;124:245–249.
            pubmed: 17140693
          47. Zinkernagel RM. On natural and artificial vaccinations. Annu. Rev. Immunol. 2003;21:515–546.
            pubmed: 12500980

          Citations

          This article has been cited 11 times.
          1. Jindra C, Hainisch EK, Brandt S. Immunotherapy of Equine Sarcoids-From Early Approaches to Innovative Vaccines. Vaccines (Basel) 2023 Mar 30;11(4).
            doi: 10.3390/vaccines11040769pubmed: 37112681google scholar: lookup
          2. Vrablikova A, Brezani V, Psikal I, Fraiberk M, Sebela M, Fojtikova M, Kulich P, Hezova R, Masek J. Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein. Front Vet Sci 2023;10:1116661.
            doi: 10.3389/fvets.2023.1116661pubmed: 37056230google scholar: lookup
          3. Hainisch EK, Jindra C, Kirnbauer R, Brandt S. Papillomavirus-like Particles in Equine Medicine. Viruses 2023 Jan 25;15(2).
            doi: 10.3390/v15020345pubmed: 36851559google scholar: lookup
          4. Munday JS, Orbell G, Fairley RA, Hardcastle M, Vaatstra B. Evidence from a Series of 104 Equine Sarcoids Suggests That Most Sarcoids in New Zealand Are Caused by Bovine Papillomavirus Type 2, although Both BPV1 and BPV2 DNA Are Detectable in around 10% of Sarcoids. Animals (Basel) 2021 Oct 29;11(11).
            doi: 10.3390/ani11113093pubmed: 34827825google scholar: lookup
          5. Munday JS, Gedye K, Daudt C, Chaves Da Silva F. The Development of Novel Primer Sets to Specifically Amplify Each of the Five Different Deltapapillomaviruses That Cause Neoplasia after Cross-Species Infection. Vet Sci 2021 Sep 26;8(10).
            doi: 10.3390/vetsci8100208pubmed: 34679038google scholar: lookup
          6. Jindra C, Kamjunke AK, Jones S, Brandt S. Screening for bovine papillomavirus type 13 (BPV13) in a European population of sarcoid-bearing equids. Equine Vet J 2021 Aug 30;54(4):662-9.
            doi: 10.1111/evj.13501pubmed: 34459020google scholar: lookup
          7. Yamashita-Kawanishi N, Haga T. Anogenital-Associated Papillomaviruses in Animals: Focusing on Bos taurus Papillomaviruses. Pathogens 2020 Nov 27;9(12).
            doi: 10.3390/pathogens9120993pubmed: 33260814google scholar: lookup
          8. Crisci E, Bárcena J, Montoya M. Virus-like particle-based vaccines for animal viral infections. Inmunologia 2013 Jul-Sep;32(3):102-116.
            doi: 10.1016/j.inmuno.2012.08.002pubmed: 32287712google scholar: lookup
          9. Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 2012 Dec 17;31(1):58-83.
            doi: 10.1016/j.vaccine.2012.10.083pubmed: 23142589google scholar: lookup
          10. Crisci E, Bárcena J, Montoya M. Virus-like particles: the new frontier of vaccines for animal viral infections. Vet Immunol Immunopathol 2012 Aug 15;148(3-4):211-25.
            doi: 10.1016/j.vetimm.2012.04.026pubmed: 22705417google scholar: lookup
          11. Hartl B, Hainisch EK, Shafti-Keramat S, Kirnbauer R, Corteggio A, Borzacchiello G, Tober R, Kainzbauer C, Pratscher B, Brandt S. Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation. J Gen Virol 2011 Oct;92(Pt 10):2437-2445.
            doi: 10.1099/vir.0.033670-0pubmed: 21715602google scholar: lookup
          Subscribe to our newsletter
          Join 99,359 horse owners like you who receive our email updates on horse health and nutrition.